What is the size of the Companion Diagnostics market in 2022?

The Companion Diagnostics market size is USD 2,452 Million in 2022.

What is the projected CAGR at which the Companion Diagnostics market is expected to grow at?

The Companion Diagnostics market is expected to grow at a CAGR of 7.1% (2023-2032).

List the segments encompassed in this report on the Companion Diagnostics market?

Market.US has segmented the Companion Diagnostics market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Product And Service the market has been segmented into S Assays, Kits And Reagents, Software And Services. By Technology the market has been segmented into Polymerase Chain Reaction, Next Generation Sequencing, In Situ Hybridization, and Immunohistochemistry. By Indication the market has been segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma. By End-User the market has been segmented into Reference Laboratories, Pharmaceutical And Biopharmaceutical Companies, and Contract Research Organizations.

List the key industry players of the Companion Diagnostics market?

Abbott (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (U.S.), QIAGEN (Germany), Myriad Genetics, Inc. (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), BIOMERIEUX (France), Myriad Genetics, Inc. (U.S.), Other Key Players.

Name the key areas of business for Companion Diagnostics?

The US, Canada, India, China, UK, Japan, & Germany are key areas of operation for the Companion Diagnostics Market.

Companion Diagnostics Market By Product And Service (Kits And Reagents, Software And Services), By Technology (Polymerase Chain Reaction, Next Generation Sequencing), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer), By End-User (Reference Laboratories , Pharmaceutical And Biopharmaceutical Companies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Published date: Aug 2024
Report ID: 57777
Number of Pages: 365
Format:

- Abbott (U.S.)
- Agilent Technologies, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Guardant Health (U.S.)
- QIAGEN (Germany)
- Myriad Genetics, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- BIOMERIEUX (France)
- Other Key Players.

Related Reports

Our Clients

Report ID 57777
Published Date Aug 2024
Rating
- ★★★★★
  
  ★★★★★
- (35)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible